{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 11 of 122', '13.6 Study Termination', '89', '14 USE OF STUDY INFORMATION AND PUBLICATION', '90', '15 REFERENCES', '92', '16 INVESTIGATOR SIGNATURE', '95', 'LIST OF TABLES', 'Table 1:', 'Order of Subject and Parent/Caregiver Questionnaires To Be Completed', '30', 'Table 2:', 'AR101 Single Doses and Cumulative Dose on Day 1', '32', 'Table 3:', 'Initial Dose-Escalation Day 1 Procedures', '33', 'Table 4:', 'Up-Dosing Dose-Escalation Schedule (3-300 mg)', '34', 'Table 5:', 'Primary Reasons for Early Discontinuation', '37', 'Table 6:', 'Follow-Up HRQOL Questionnaires for Subjects Receiving AR101 Treatment Who', 'Discontinue Early', '39', 'Table 7:', 'Prohibited Medications', '45', 'Table 8:', 'Criteria for Serious Adverse Events', '47', 'Table 9:', 'CoFAR Severity Grading System for Allergic Reactions', '48', 'Table 10:', 'EAACI Severity Grading System for Anaphylaxis', '49', 'Table 11:', 'NCI CTCAE Severity Grading System for Adverse Events', '49', 'Table 12:', 'Allergy Symptom Severity and Study Product Dose Tolerability', '52', 'Table 13:', 'Description of Actions to Be Taken With Study Product Dosing for Allergy Symptoms on', 'Initial Dose-Escalation Day 1', '55', 'Table 14:', 'Description of Actions to Be Taken With Study Product Dosing for Allergy Symptoms', 'During Up-Dosing and Maintenance', '58', 'Table 15:', 'Dose Adjustment of Study Product After Treatment With Antihistamines and Epinephrine for', 'Dose-Related Allergy Symptoms During Up-Dosing and Maintenance', '60', 'Table 16:', 'Study Product Dose Re-Escalation After Dose Reduction for Reasons Other Than Allergic', 'Reactions', '61', 'Table 17:', 'Procedures for Missed Consecutive Doses of Study Product', '62', 'Table 18:', 'Summary of Instruments for Subject- and Parent/Caregiver-Reported HRQOL and Other', 'Outcomes', '70', 'Table 19:', 'Evaluation of Asthma Based on NHLBI Criteria', '76', 'Table 20:', 'Clinical Laboratory Tests', '84', 'LIST OF FIGURES', 'Figure 1:', 'Study Schematic', '24', 'Figure 2:', 'Management of Study Product Dosing for Allergy Symptoms on Initial Dose-Escalation', 'Day 1', '54', 'Figure 3:', 'Management of Study Product Dosing for Allergy Symptoms During Up-Dosing and', 'Maintenance', '57', 'Figure 4:', 'Adverse Event Reporting Period', '66', 'LIST OF APPENDICES', 'Appendix 1: Open-Label Food Challenge Procedures', '96']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 12 of 122', 'Appendix 2: Real-World Food Challenge Procedures', '104', 'Appendix 3: Study Schedule of Activities for All Subjects: Screening (Days -28 to -1)', '110', 'Appendix 4: Study Schedule of Activities for AR101 Treatment: Initial Dose Escalation and Up-Dosing', '112', 'Appendix 5: Study Schedule of Activities for AR101 Treatment: Maintenance', '115', 'Appendix 6: Study Schedule of Activities for Standard of Care Alone', '119', 'Appendix 7: Study Schedule of Activities for Subjects Who Discontinue Treatment Early or Exit With', 'Ongoing Adverse Event: Safety Follow-Up', '122']\n\n###\n\n", "completion": "END"}